Magnetic blood clot dissolver could be 4,000 times more efficient than enzyme treatment

Blood cells
Blood clot
Magnetic particles combined with enzymes break
down a blood clot.--Courtesy of ITMO U.

Researchers at ITMO University in St. Petersburg, Russia, have developed a magnetically controlled treatment designed to dissolve blood clots. The method looks to be a promising solution to some of the complications associated with enzyme-based thrombolytic drugs.

To make the targeted drug, the scientists combined the mineral magnetite with the enzyme urokinase, commonly used as a thrombolytic agent. The nanosized particles can then be localized around a blood clot using an external magnetic field. And the magnetite framework also acts as protection for the enzyme, which can be deactivated by inhibitors in the blood.

The combination demonstrated up to 4,000 times more efficiency than the enzyme-based drugs alone, according to the university, drastically reducing doses. Normally, the enzyme is administered in a “knock-out” dose to ensure a small portion reaches the clot, but the targeted approach requires a much smaller (and less dangerous) amount.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The results of the in vitro study were published in the journal Scientific Reports.

"Now we are using a sledgehammer to crack a nut,” Ivan Dudanov of St. Petersburg’s Mariinsky Hospital said in a statement. "Dissolving a little blood clot that blocked a vessel of only 1-2 mm in diameter, thrombolytic drugs negatively affect the entire network of blood vessels. In order to change the situation, we decided to develop a method of targeted drug delivery that would allow us to considerably reduce the dosage and ensure that the whole therapeutic effect is focused on the clot.”

- here's the ITMO release

Related Articles:
CMS flogs Theranos for quality issues with blood clot test: WSJ
Study: Heated chemo-delivering nanoparticles kill 95% of ovarian cancer cells